Insights  ||| S:0 E:9 ||| NNS
and  ||| S:9 E:13 ||| CC
perspectives  ||| S:13 E:26 ||| NN
in  ||| S:26 E:29 ||| IN
the  ||| S:29 E:33 ||| DT
clinical  ||| S:33 E:42 ||| JJ
and  ||| S:42 E:46 ||| CC
operational  ||| S:46 E:58 ||| JJ
management  ||| S:58 E:69 ||| NN
of  ||| S:69 E:72 ||| IN
cancer-related  ||| S:72 E:87 ||| JJ
anemia  ||| S:87 E:94 ||| JJ
Management  ||| S:94 E:105 ||| NN
of  ||| S:105 E:108 ||| IN
anemia  ||| S:108 E:115 ||| NN
in  ||| S:115 E:118 ||| IN
patients  ||| S:118 E:127 ||| NNS
with  ||| S:127 E:132 ||| IN
cancer  ||| S:132 E:139 ||| NN
presents  ||| S:139 E:148 ||| VBZ
challenges  ||| S:148 E:159 ||| NNS
from  ||| S:159 E:164 ||| IN
clinical ||| S:164 E:172 ||| JJ
,  ||| S:172 E:174 ||| ,
operational ||| S:174 E:185 ||| JJ
,  ||| S:185 E:187 ||| ,
and  ||| S:187 E:191 ||| CC
economic  ||| S:191 E:200 ||| JJ
perspectives ||| S:200 E:212 ||| NN
.  ||| S:212 E:214 ||| .
Clinically ||| S:214 E:224 ||| NNP
,  ||| S:224 E:226 ||| ,
anemia  ||| S:226 E:233 ||| NN
in  ||| S:233 E:236 ||| IN
these  ||| S:236 E:242 ||| DT
patients  ||| S:242 E:251 ||| NNS
may  ||| S:251 E:255 ||| MD
result  ||| S:255 E:262 ||| VB
from  ||| S:262 E:267 ||| IN
treatment  ||| S:267 E:277 ||| NN
( ||| S:277 E:278 ||| -LRB-
chemotherapy ||| S:278 E:290 ||| UH
,  ||| S:290 E:292 ||| ,
radiation  ||| S:292 E:302 ||| NN
therapy ||| S:302 E:309 ||| NN
,  ||| S:309 E:311 ||| ,
or  ||| S:311 E:314 ||| CC
surgical  ||| S:314 E:323 ||| JJ
interventions ||| S:323 E:336 ||| NNS
)  ||| S:336 E:338 ||| -RRB-
or  ||| S:338 E:341 ||| CC
from  ||| S:341 E:346 ||| IN
the  ||| S:346 E:350 ||| DT
malignancy  ||| S:350 E:361 ||| NN
itself ||| S:361 E:367 ||| PRP
.  ||| S:367 E:369 ||| .
Anemia  ||| S:369 E:376 ||| NNP
not  ||| S:376 E:380 ||| RB
only  ||| S:380 E:385 ||| RB
contributes  ||| S:385 E:397 ||| VBZ
to  ||| S:397 E:400 ||| TO
cancer-related  ||| S:400 E:415 ||| JJ
fatigue  ||| S:415 E:423 ||| NN
and  ||| S:423 E:427 ||| CC
other  ||| S:427 E:433 ||| JJ
quality  ||| S:433 E:441 ||| NN
of  ||| S:441 E:444 ||| IN
life  ||| S:444 E:449 ||| NN
issues ||| S:449 E:455 ||| NNS
,  ||| S:455 E:457 ||| ,
but  ||| S:457 E:461 ||| CC
also  ||| S:461 E:466 ||| RB
affects  ||| S:466 E:474 ||| VBZ
prognosis ||| S:474 E:483 ||| VBN
.  ||| S:483 E:485 ||| .
From  ||| S:485 E:490 ||| IN
the  ||| S:490 E:494 ||| DT
operational  ||| S:494 E:506 ||| JJ
perspective ||| S:506 E:517 ||| NN
,  ||| S:517 E:519 ||| ,
a  ||| S:519 E:521 ||| DT
patient  ||| S:521 E:529 ||| NN
with  ||| S:529 E:534 ||| IN
cancer  ||| S:534 E:541 ||| NN
who  ||| S:541 E:545 ||| WP
is  ||| S:545 E:548 ||| VBZ
also  ||| S:548 E:553 ||| RB
anemic  ||| S:553 E:560 ||| RB
may  ||| S:560 E:564 ||| MD
consume  ||| S:564 E:572 ||| VB
more  ||| S:572 E:577 ||| JJR
laboratory ||| S:577 E:587 ||| NN
,  ||| S:587 E:589 ||| ,
pharmacy ||| S:589 E:597 ||| NN
,  ||| S:597 E:599 ||| ,
and  ||| S:599 E:603 ||| CC
clinical  ||| S:603 E:612 ||| JJ
resources  ||| S:612 E:622 ||| NNS
than  ||| S:622 E:627 ||| IN
other  ||| S:627 E:633 ||| JJ
patients  ||| S:633 E:642 ||| NNS
with  ||| S:642 E:647 ||| IN
cancer ||| S:647 E:653 ||| NN
.  ||| S:653 E:655 ||| .
